Tim Riley has been involved with the commercialization of mass spectrometry instrumentation since 1984 when he joined VG Instruments, which was acquired by Fisons Instruments in 1990, and then spun off as Micromass in 1996. Then, in 1997, Waters purchased Micromass and Riley served as president of the US sales and services division. Currently, Riley is vice president of proteomics business development for Waters. BioCommerce Week spoke to Riley recently to get a view of the company’s business development strategy for proteomics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.